2023
The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
d'Andrea G, Pettorruso M, Di Lorenzo G, Rhee T, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, Di Nicola M, Andriola I, Marcatili M, Clerici M, Dell'Osso B, Sensi S, Mansur R, Rosenblat J, Martinotti G, McIntyre R. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data. Journal Of Affective Disorders 2023, 348: 314-322. PMID: 38145840, DOI: 10.1016/j.jad.2023.12.038.Peer-Reviewed Original ResearchTreatment-resistant depressionSide effectsIntranasal esketamineIntravenous ketamineRemission rateDepressive symptomsCanadian Rapid Treatment CenterShort-term antidepressant effectSuperior remission ratesAcute treatment phaseLong-term efficacyHigh response rateEffect sizeMore discontinuationsQIDS-SR16TRD cohortAntidepressant effectsDiscontinuation ratesAcute treatmentAdverse eventsPrimary outcomeLow side effectsAntidepressant effectivenessHead studiesQuick Inventory
2019
Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults
Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC, Baker WL. Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. Journal Of The American Geriatrics Society 2019, 67: 1571-1581. PMID: 31140587, DOI: 10.1111/jgs.15966.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsMajor depressive disorderOverall adverse eventsAdverse eventsYears of ageStudy withdrawalAcute phaseReuptake inhibitorsObservational studyAdverse effectsChoice of antidepressantSerious adverse eventsAcute treatment phaseNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsSpecific adverse eventsComparative long-term studiesNonpharmacologic therapiesContinuation treatmentPatients 65Pharmacologic treatmentQTc prolongationMore fallsOutpatient setting
2018
Exploring Antidepressant Adherence at a Student-Run Free Mental Health Clinic
Mann C, Rifkin R, Nabel E, Thomas D, Meah Y, Katz C. Exploring Antidepressant Adherence at a Student-Run Free Mental Health Clinic. Community Mental Health Journal 2018, 55: 57-62. PMID: 30062631, DOI: 10.1007/s10597-018-0301-5.Peer-Reviewed Original ResearchConceptsEast Harlem Health Outreach PartnershipNew York StateMental healthStudent-runNew York State MedicaidAcute treatment phaseMental health clinicsLow treatment ratesHEDIS criteriaMH clinicsAntidepressant adherenceHealth clinicsPhysician notesDepression treatmentAdherence ratesMeasure adherenceLow adherencePharmacy dataTreatment phaseTreatment ratesInsurance providersAdherenceMinority groupsMedicaidClinic
2017
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply